Crystalline form of 2-{4-['3-(4-chloro-2-fluorophenyl)-4-pyrimidin-4-yl-1h-pyrazol-5-yl]piperidin-1-yl}-2-oxoethanol

Crystalline form of 2-{4-['3-(4-chloro-2-fluorophenyl)-4-pyrimidin-4-yl-1h-pyrazol-5-yl]piperidin-1-yl}-2-oxoethanol

Crystalline form of the p38 kinase inhibitor 2-{4-[3-(4-chloro-2-fluorophenyl)-4-pyrimidin-4-yl-1H-pyra-zol-5-yl]piperidin-1-yl}-2-oxoethanol can be used, is provided. The crystalline form is a hydrated crystalline form. Also provided are combinations and pharmaceutical compositions comprising the c...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Hauptverfasser: SCHARTMAN RICHARD R, HOFFMAN DOUGLAS H
Format: Patent
Sprache:eng
Schlagworte:
CHEMISTRY
HETEROCYCLIC COMPOUNDS
HUMAN NECESSITIES
HYGIENE
MEDICAL OR VETERINARY SCIENCE
METALLURGY
ORGANIC CHEMISTRY
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
Online-Zugang:Volltext bestellen
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Crystalline form of the p38 kinase inhibitor 2-{4-[3-(4-chloro-2-fluorophenyl)-4-pyrimidin-4-yl-1H-pyra-zol-5-yl]piperidin-1-yl}-2-oxoethanol can be used, is provided. The crystalline form is a hydrated crystalline form. Also provided are combinations and pharmaceutical compositions comprising the crystalline form, process for preparing the crystalline form and for preparing compositions comprising the crystalline form, in methods for the prophylaxis and/or treatment of a p38 kinase-mediated condition comprising administering to a subject a therapeutically effective amount of the crystalline form of 1.